GPR52 MODULATORS AND METHODS OF USE
The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.
1 . A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
X and Y are independently N or CH;
Q is N or CR 7 ;
Z is
R 1 is hydrogen, halogen, C 1 -C 6 alkyl or haloC 1 -C 6 alkyl;
R 2 is hydrogen, halogen, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, or —OR A ;
R 3 is hydrogen, halogen, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl;
R 4 , R 5 , R 6 , and R 7 , are independently hydrogen, halogen, cyano, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —OR B , —S(O) m R B , or —S(O) p N(R B R C );
R 8 , R 9 , and R 10 are independently hydrogen, halogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —C(═O)R D , —OR E , or —(CH 2 ) n C(═O)N(R E R F ); or wherein R 8 and R 9 , or R 9 and R 10 , with the carbon atom to which they are attached, together form a 6 membered heterocyclyl group, said 6 membered heterocyclyl group optionally substituted with ═O;
each R A , R B , R C , R E , and R F , is independently hydrogen, C 1 -C 6 alkyl, or haloC 1 -C 6 alkyl; or
wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group;
each R D is independently hydrogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0, 1, 2 or 3; and
each p is independently 1 or 2.
2 . The compound of claim 1 , wherein one of X and Y is CH, and the other of X and Y is N.
3 . The compound of claim 1 , wherein X and Y are each N.
4 . The compound of claim 1 , wherein X and Y are each CH.
5 . The compound of any one of claims 1-4 , wherein R 1 is halogen.
6 . The compound of any one of claims 1-5 , wherein R 1 is fluoro or chloro.
7 . The compound of any one of claims 1-4 , wherein R 1 is C 1 -C 6 alkyl.
8 . The compound of any one of claims 1-4 or 7 , wherein R 1 is methyl.
9 . The compound of any one of claims 1-4 , wherein R 1 is haloC 1 -C 6 alkyl.
10 . The compound of any one of claims 1-4 or 9 , wherein R 1 is trifluoromethyl.
11 . The compound of any one of claims 1-4 , wherein R 1 is hydrogen.
12 . The compound of any one of claims 1-11 , wherein R 2 is halogen.
13 . The compound of any one of claims 1-12 , wherein R 2 is fluoro or chloro.
14 . The compound of any one of claims 1-11 , wherein R 2 is C 1 -C 3 alkyl.
15 . The compound of any one of claims 1-11 or 14 , wherein R 2 is methyl.
16 . The compound of any one of claims 1-11 , wherein R 2 is haloC 1 -C 3 alkyl.
17 . The compound of any one of claims 1-11 or 16 , wherein R 2 is trifluoromethyl.
18 . The compound of any one of claims 1-11 , wherein R 2 is hydrogen.
19 . The compound of any one of claims 1-11 , wherein R 2 is —OR A .
20 . The compound of any one of claims 1-11 or 19 , wherein R A is C 1 -C 6 alkyl.
21 . The compound of claim 19 or 20 , wherein R A is methyl.
22 . The compound of any one of claims 1-11 or 19 , wherein R A is haloC 1 -C 6 alkyl.
23 . The compound of claim 19 or 22 , wherein R A is trifluoromethyl.
24 . The compound of any one of claims 1-11 or 19 , wherein R A is hydrogen.
25 . The compound of any one of claims 1-24 , wherein R 3 is halogen.
26 . The compound of any one of claims 1-25 , wherein R 3 is fluoro or chloro.
27 . The compound of any one of claims 1-24 , wherein R 3 is C 1 -C 3 alkyl.
28 . The compound of any one of claims 1-24 or 27 , wherein R 3 is methyl.
29 . The compound of any one of claims 1-24 , wherein R 3 is haloC 1 -C 3 alkyl.
30 . The compound of any one of claims 1-24 or 29 , wherein R 3 is trifluoromethyl.
31 . The compound of any one of claims 1-24 , wherein R 3 is hydrogen.
32 . The compound of any one of claims 1-31 , wherein R 4 is halogen.
33 . The compound of any one of claims 1-32 , wherein R 4 is fluoro or chloro.
34 . The compound of any one of claims 1-31 , wherein R 4 is C 1 -C 6 alkyl.
35 . The compound of any one of claims 1-31 or 34 , wherein R 4 is methyl.
36 . The compound of any one of claims 1-31 , wherein R 4 is haloC 1 -C 6 alkyl.
37 . The compound of any one of claims 1-31 or 36 , wherein R 4 is trifluoromethyl.
38 . The compound of any one of claims 1-31 , wherein R 4 is hydrogen.
39 . The compound of any one of claims 1-31 , wherein R 4 is cyano.
40 . The compound of any one of claims 1-39 , wherein R 5 is halogen.
41 . The compound of any one of claims 1-40 , wherein R 5 is fluoro or chloro.
42 . The compound of any one of claims 1-39 , wherein R 5 is C 1 -C 6 alkyl.
43 . The compound of any one of claims 1-39 or 42 , wherein R 5 is methyl.
44 . The compound of any one of claims 1-39 , wherein R 5 is haloC 1 -C 6 alkyl.
45 . The compound of any one of claims 1-39 or 44 , wherein R 5 is trifluoromethyl.
46 . The compound of any one of claims 1-39 , wherein R 5 is hydrogen.
47 . The compound of any one of claims 1-39 , wherein R 5 is cyano.
48 . The compound of any one of claims 1-47 , wherein R 6 is halogen.
49 . The compound of any one of claims 1-48 , wherein R 6 is fluoro or chloro.
50 . The compound of any one of claims 1-47 , wherein R 6 is C 1 -C 6 alkyl.
51 . The compound of any one of claims 1-47 or 50 , wherein R 6 is methyl.
52 . The compound of any one of claims 1-47 , wherein R 6 is haloC 1 -C 6 alkyl.
53 . The compound of any one of claims 1-47 or 52 , wherein R 6 is trifluoromethyl.
54 . The compound of any one of claims 1-47 , wherein R 6 is hydrogen.
55 . The compound of any one of claims 1-47 , wherein R 6 is cyano.
56 . The compound of any one of claims 1-55 , wherein Q is CR 7 .
57 . The compound of any one of claims 1-56 , wherein R 7 is halogen.
58 . The compound of any one of claims 1-57 , wherein R 7 is fluoro or chloro.
59 . The compound of any one of claims 1-56 , wherein R 7 is C 1 -C 6 alkyl.
60 . The compound of any one of claims 1-56 or 59 , wherein R 7 is methyl.
61 . The compound of any one of claims 1-56 , wherein R 7 is haloC 1 -C 6 alkyl.
62 . The compound of any one of claims 1-56 or 61 , wherein R 7 is trifluoromethyl.
63 . The compound of any one of claims 1-56 , wherein R 7 is hydrogen.
64 . The compound of any one of claims 1-56 , wherein R 7 is cyano.
65 . The compound of any one of claims 1-55 , wherein Q is N.
66 . The compound of any one of claims 1-31 or 40-65 , wherein R 4 is —OR B .
67 . The compound of any one of claims 1-39 or 48-65 , wherein R 5 is —OR B .
68 . The compound of any one of claims 1-47 or 56-65 , wherein R 6 is —OR B .
69 . The compound of any one of claims 1-56 , wherein R 7 is —OR B .
70 . The compound of any one of claims 1-31 or 40-65 , wherein R 4 is —S(O) m R B .
71 . The compound of any one of claims 1-39 or 48-65 , wherein R 5 is —S(O) m R B .
72 . The compound of any one of claims 1-47 or 56-65 , wherein R 6 is —S(O) m R B .
73 . The compound of any one of claims 1-56 , wherein R 7 is —S(O) m R B .
74 . The compound of any one of claims 1-31 or 70-73 , wherein m is 0.
75 . The compound of any one of claims 1-31 or 70-73 , wherein m is 1.
76 . The compound of any one of claims 1-31 or 70-73 , wherein m is 2.
77 . The compound of any one of claims 1-31 or 40-65 , wherein R 4 is —S(O) p N(R B R C ).
78 . The compound of any one of claims 1-39 or 48-65 , wherein R 5 is —S(O) p N(R B R C ).
79 . The compound of any one of claims 1-47 or 56-65 , wherein R 6 is —S(O) p N(R B R C ).
80 . The compound of any one of claims 1-56 , wherein R 7 is —S(O) p N(R B R C ).
81 . The compound of any one of claims 1-31 or 77-80 , wherein p is 1.
82 . The compound of any one of claims 1-31 or 77-80 , wherein p is 2.
83 . The compound of any one of claims 1-82 , wherein R B is C 1 -C 6 alkyl.
84 . The compound of any one of claims 1-83 , wherein R B is methyl.
85 . The compound of any one of claims 1-82 , wherein R B is haloC 1 -C 6 alkyl.
86 . The compound of any one of claims 1-82 or 85 , wherein R B is trifluoromethyl.
87 . The compound of any one of claims 1-82 , wherein R B is hydrogen.
88 . The compound of any one of claims 1-87 , wherein R c is C 1 -C 6 alkyl.
89 . The compound of any one of claims 1-88 , wherein R c is methyl.
90 . The compound of any one of claims 1-87 , wherein R c is haloC 1 -C 6 alkyl.
91 . The compound of any one of claims 1-87 or 90 , wherein R c is trifluoromethyl.
92 . The compound of any one of claims 1-87 , wherein R c is hydrogen.
93 . The compound of any one of claims 1-92 , wherein Z is
94 . The compound of any one of claims 1-92 , wherein Z is
95 . The compound of any one of claims 1-94 , wherein R 8 is halogen.
96 . The compound of any one of claims 1-95 , wherein R 8 is fluoro or chloro.
97 . The compound of any one of claims 1-94 , wherein R 8 is C 1 -C 6 alkyl.
98 . The compound of any one of claims 1-94 or 97 , wherein R 8 is methyl.
99 . The compound of any one of claims 1-94 , wherein R 8 is haloC 1 -C 6 alkyl.
100 . The compound of any one of claims 1-94 or 99 , wherein R 8 is trifluoromethyl.
101 . The compound of any one of claims 1-94 , wherein R 8 is hydrogen.
102 . The compound of any one of claims 1-94 , wherein R 8 is —OR E .
103 . The compound of any one of claims 1-94 , wherein R 8 is —C(O)R D .
104 . The compound of any one of claims 1-94 , wherein R 8 is —(CH 2 ) n C(═O)N(R E R F ).
105 . The compound of any one of claims 1-104 , wherein R 9 is halogen.
106 . The compound of any one of claims 1-105 , wherein R 9 is fluoro or chloro.
107 . The compound of any one of claims 1-104 , wherein R 9 is C 1 -C 6 alkyl.
108 . The compound of any one of claims 1-104 or 107 , wherein R 9 is methyl.
109 . The compound of any one of claims 1-104 , wherein R 9 is haloC 1 -C 6 alkyl.
110 . The compound of any one of claims 1-104 or 109 , wherein R 9 is trifluoromethyl.
111 . The compound of any one of claims 1-104 , wherein R 9 is hydrogen.
112 . The compound of any one of claims 1-104 , wherein R 9 is —OR E .
113 . The compound of any one of claims 1-104 , wherein R 9 is —C(═O)R D .
114 . The compound of any one of claims 1-104 , wherein R 9 is —(CH 2 ) n C(═O)N(R E R F ).
115 . The compound of any of claims 1-94 , wherein R 8 and R 9 , with the carbon atom to which they are attached, together form a 6 membered heterocyclyl group.
116 . The compound of claim 115 , wherein the 6 membered heterocyclyl group is a piperidone.
117 . The compound of any one of claims 1-116 , wherein R 10 is halogen.
118 . The compound of any one of claims 1-117 , wherein R 10 is fluoro or chloro.
119 . The compound of any one of claims 1-116 , wherein R 10 is C 1 -C 6 alkyl.
120 . The compound of any one of claims 1-116 or 119 , wherein R 10 is methyl.
121 . The compound of any one of claims 1-116 , wherein R 10 is haloC 1 -C 6 alkyl.
122 . The compound of any one of claims 1-116 or 121 , wherein R 10 is trifluoromethyl.
123 . The compound of any one of claims 1-116 , wherein R 10 is hydrogen.
124 . The compound of any one of claims 1-116 , wherein R 10 is —OR E .
125 . The compound of any one of claims 1-116 , wherein R 10 is —C(═O)R D .
126 . The compound of any one of claims 1-116 , wherein R 10 is —(CH 2 ) n C(═O)N(R E R F ).
127 . The compound of any of claims 1-104 , wherein R 9 and R 10 , with the carbon atom to which they are attached, together form a 6 membered heterocyclyl group.
128 . The compound of claim 127 , wherein the 6 membered heterocyclyl group is piperidine or piperazine.
129 . The compound of any one of claims 1-128 , wherein n is 0.
130 . The compound of any one of claims 1-128 , wherein n is 1.
131 . The compound of any one of claims 1-128 , wherein n is 2.
132 . The compound of any one of claims 1-128 , wherein n is 3.
133 . The compound of any one of claims 1-132 , wherein R D is C 1 -C 6 alkyl.
134 . The compound of any one of claims 1-133 , wherein R D is methyl.
135 . The compound of any one of claims 1-132 , wherein R D is haloC 1 -C 6 alkyl.
136 . The compound of any one of claims 1-132 or 135 , wherein R D is trifluoromethyl.
137 . The compound of any one of claims 1-132 , wherein R D is hydrogen.
138 . The compound of any one of claims 1-132 , wherein R D is —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH.
139 . The compound of any one of claims 1-132 or 138 , wherein R D is —NH 2 .
140 . The compound of any one of claims 1-132 or 138 , wherein R D is —NHCH 2 CH 2 CH 2 OH.
141 . The compound of any one of claims 1-132 or 138 , wherein R D is —NHCH 2 CH 2 CH 2 CH 2 OH.
142 . The compound of any one of claims 1-141 , wherein R E is C 1 -C 6 alkyl.
143 . The compound of any one of claims 1-142 , wherein R E is methyl.
144 . The compound of any one of claims 1-141 , wherein R E is haloC 1 -C 6 alkyl.
145 . The compound of any one of claims 1-141 or 144 , wherein R E is trifluoromethyl.
146 . The compound of any one of claims 1-142 , wherein R E is hydrogen.
147 . The compound of any one of claims 1-146 , wherein R F is C 1 -C 6 alkyl.
148 . The compound of any one of claims 1-147 , wherein R F is methyl.
149 . The compound of any one of claims 1-146 , wherein R F is haloC 1 -C 6 alkyl.
150 . The compound of any one of claims 1-146 or 149 , wherein R F is trifluoromethyl.
151 . The compound of any one of claims 1-146 , wherein R F is hydrogen.
152 . The compound of any one of claims 1-141 , wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group.
153 . The compound of claim 152 , wherein the 5-6 membered heterocyclyl group is piperazine.
154 . The compound of claim 1 , wherein Z is
155 . A compound of Formula (IA):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or halogen;
R 2 and R 3 are each hydrogen;
R 4 is hydrogen or halogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen, halogen, or
R 7 is hydrogen, halogen, or haloC 1 -C 3 alkyl;
R 8 is hydrogen, halogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —C(═O)R D , —OR E , or —(CH 2 ) n C(═O)N(R E R F );
R 9 is hydrogen, —C(═O)R D , or —(CH 2 ) n C(═O)N(R E R F ); or
R 10 is hydrogen or C 1 -C 3 alkyl;
each R B , R E , and R F , is independently hydrogen, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl; or
wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0 or 1; and
each p is independently 1 or 2.
156 . A compound of Formula (IB):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or halogen;
R 2 and R 3 are each hydrogen;
R 4 is hydrogen or halogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen, halogen, or —OR B ;
R 7 is hydrogen, halogen, or haloC 1 -C 3 alkyl;
R 8 is hydrogen, halogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —C(═O)R D , —OR E , or —(CH 2 ) n C(═O)N(R E R F );
R 9 is hydrogen, —C(═O)R D , or —(CH 2 ) n C(═O)N(R E R F ); or
R 10 is hydrogen or C 1 -C 3 alkyl;
each R B , R E , and R F , is independently hydrogen, C 1 -C 6 alkyl, or haloC 1 -C 6 alkyl; or
wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group;
each R D is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0 or 2; and
each n is independently 0, 1, 2 or 3.
157 . A compound of Formula (IC):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or halogen;
R 2 and R 3 are each hydrogen;
R 4 is hydrogen or halogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen, halogen, or
R 8 is hydrogen, halogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —C(═O)R D , —OR E , or —(CH 2 ) n C(═O)N(R E R F );
R 9 is hydrogen, —C(═O)R D , or —(CH 2 ) n C(═O)N(R E R F ); or
R 10 is hydrogen or C 1 -C 3 alkyl;
each R B , R E , and R F , is independently hydrogen, C 1 -C 6 alkyl, or haloC 1 -C 6 alkyl; or
wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group;
each R D is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2; and
each n is independently 0, 1, 2 or 3.
158 . A compound of Formula (ID):
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen or halogen;
R 2 and R 3 are each hydrogen;
R 4 is hydrogen or halogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 3 alkyl, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen, halogen, or
R 8 is hydrogen, halogen, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —C(═O)R D , —OR E , or —(CH 2 ) n C(═O)N(R E R F );
R 9 is hydrogen, —C(═O)R D , or —(CH 2 ) n C(═O)N(R E R F ); or
R 10 is hydrogen or C 1 -C 3 alkyl;
each R B , R E , and R F , is independently hydrogen, C 1 -C 6 alkyl, or haloC 1 -C 6 alkyl; or
wherein R E and R F , with the nitrogen atom to which they are attached, together form a 5-6 membered heterocyclyl group;
each R D is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0, 1, 2 or 3; and
each p is independently 1 or 2.
159 . The compound of any one of claims 155-158 , wherein
is:
160 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is CH, CF, CCl, or CCF 3 ;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is halogen, cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl;
R 6 is hydrogen or fluoro;
R 8 is hydrogen, halogen, or C 1 -C 6 alkyl;
R 9 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
each R D is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH; and
each n is independently 0 or 1.
161 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is CH, CF, CCl, or CCF 3 ;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —OR B , —S(O) m R B , or
S(O) p N(R B R C );
R 6 is hydrogen or fluoro;
R 8 is hydrogen, halogen, or C 1 -C 6 alkyl;
R 9 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0 or 1; and
each p is independently 1 or 2.
162 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is N;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is halogen, cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl;
R 6 is hydrogen or fluoro;
R 8 is hydrogen, halogen, or C 1 -C 6 alkyl;
R 9 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH; and
each n is independently 0 or 1.
163 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is N;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —OR B , —S(O) m R B , or
S(O) p N(R B R C );
R 6 is hydrogen or fluoro;
R 8 is hydrogen, halogen, or C 1 -C 6 alkyl;
R 9 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
each R D is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0 or 1; and
each p is independently 1 or 2.
164 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is CH, CF, CCl, or CCF 3 ;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is halogen, cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl;
R 6 is hydrogen or fluoro;
R 8 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
R 9 is hydrogen, halogen, or C 1 -C 6 alkyl;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH; and
each n is independently 0 or 1.
165 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is CH, CF, CCl, or CCF 3 ;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —OR B , —S(O) m R B , or
S(O) p N(R B R C );
R 6 is hydrogen or fluoro;
R 8 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
R 9 is hydrogen, halogen, or C 1 -C 6 alkyl;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0 or 1; and
each p is independently 1 or 2.
166 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is N;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is halogen, cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl;
R 6 is hydrogen or fluoro;
R 8 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
R 9 is hydrogen, halogen, or C 1 -C 6 alkyl;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH; and
each n is independently 0 or 1.
167 . The compound of any one of claim 1 or 155-159 , wherein:
X is N;
Y is CH;
Q is N;
R 1 is hydrogen or fluoro;
R 2 , R 3 , R 4 and R 10 , are each hydrogen;
R 5 is hydrogen, halogen, cyano, C 1 -C 6 alkyl, haloC 1 -C 6 alkyl, —OR B , —S(O) m R B , or
—S(O) p N(R B R C );
R 6 is hydrogen or fluoro;
R 8 is —C(═O)R D or —(CH 2 ) n C(═O)NH 2 ;
R 9 is hydrogen, halogen, or C 1 -C 6 alkyl;
each R 1 is independently —NH 2 , —NHCH 2 CH 2 OH, —NHCH 2 CH 2 CH 2 OH or —NHCH 2 CH 2 CH 2 CH 2 OH;
each m is independently 0, 1, or 2;
each n is independently 0 or 1; and
each p is independently 1 or 2.
168 . The compound of any one of claim 1 or 155-167 , wherein Q is CH or CF; and R 1 is hydrogen.
169 . The compound of any one of claim 1 or 155-167 , wherein Q is CH or CF; and R 1 is fluoro.
170 . The compound of any one of claim 1 or 155-169 , wherein R 8 is hydrogen; and R 9 is —C(═O)NH 2 or —CH 2 C(═O)NH 2 ;
171 . The compound of any one of claim 1 or 155-169 , wherein R 8 is methyl; and R 9 is —C(═O)NH 2 or —CH 2 C(═O)NH 2 ;
172 . The compound of any one of claim 1 or 155-169 , wherein R 8 is fluoro; and R 9 is —C(═O)NH 2 or —CH 2 C(═O)NH 2 ;
173 . The compound of any one of claim 1 or 155-172 , wherein R 5 is fluoro, cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl.
174 . The compound of any one of claim 1 or 155-172 , wherein R 5 is cyano, C 1 -C 3 alkyl, or haloC 1 -C 3 alkyl.
175 . A compound of Formula (IE), wherein:
R 5 is halogen, cyano, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen or halogen;
R 7 is hydrogen or halogen;
R 8 is C 1 -C 3 alkyl or haloC 1 -C 3 alkyl;
each R B is independently C 1 -C 3 alkyl or haloC 1 -C 3 alkyl;
R E and R F are independently hydrogen; or R E and R F , with the nitrogen atom to which they are attached, together form a 6 membered heterocyclyl group; and
each m is independently 0, 1, or 2.
176 . The compound of claim 175 , wherein R 7 is hydrogen.
177 . The compound of claim 175 , wherein R 7 is fluoro.
178 . The compound of claim 175 , wherein R 7 is chloro.
179 . A compound of Formula (IF), wherein:
R 5 is halogen, cyano, haloC 1 -C 3 alkyl, —OR B , —S(O) m R B ;
R 6 is hydrogen or halogen;
R 8 is C 1 -C 3 alkyl or haloC 1 -C 3 alkyl;
each R B is independently C 1 -C 3 alkyl or haloC 1 -C 3 alkyl;
R E and R F are independently hydrogen; or R E and R F , with the nitrogen atom to which they are attached, together form a 6 membered heterocyclyl group; and
each m is independently 0, 1, or 2.
180 . The compound of any one of claims 175-179 , wherein R 8 is methyl.
181 . The compound of any one of claims 175-180 , wherein R E and R F are each hydrogen.
182 . The compound of any one of claims 175-180 , wherein R E and R F , with the nitrogen atom to which they are attached, together form a piperazine.
183 . The compound of any one of claims 175-182 , wherein R 6 is hydrogen.
184 . The compound of any one of claims 175-182 , wherein R 6 is fluoro.
185 . The compound of any one of claims 175-182 , wherein R 5 is cyano.
186 . The compound of any one of claims 175-182 , wherein R 5 is —CF 3 .
187 . The compound of any one of claims 175-182 , wherein R 5 is fluoro.
188 . The compound of any one of claims 175-182 , wherein R 5 is —OCH 3 .
189 . The compound of any one of claims 175-182 , wherein R 5 is —SCH 3 .
190 . The compound of any one of claims 175-182 , wherein R 5 is —S(O 2 )CH 3 .
191 . The compound of claim 1 , wherein
192 . The compound of claim 1 , wherein
193 . The compound of claim 1 , wherein
194 . The compound of any one of claims 191-193 , wherein X is N and Y is CH.
195 . The compound of any one of claims 191-194 , wherein R 1 , R 2 , R 3 , and R 4 , are each hydrogen.
196 . The compound of any one of claims 191-195 , wherein Q is N, CH, CCl, or CF.
197 . The compound of any one of claims 191-196 , wherein R 5 is fluoro, cyano, —CF 3 , —OCH 3 , —SCH 3 , or —S(O 2 )CH 3 .
198 . The compound of any one of claims 191-197 , wherein R 6 is hydrogen or fluoro.
199 . A pharmaceutical composition comprising a compound of any one of claims 1-198 , or a pharmaceutically acceptable salt thereof, at one or more excipients.
200 . A method of treating a neurological disorder, comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-198 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 199 ; wherein the neurological disorder is selected from the group consisting of:
schizophrenia, cognitive impairment, a panic disorder, a phobic disorder, drug-induced psychotic disorder, delusional psychosis, neuroleptic-induced dyskinesia, Parkinson's disease, drug-induced Parkinson's syndrome, extrapyramidal syndrome, Alzheimer's Disease, Lewy Body Dementia, bipolar disorder, ADHD, Tourette's syndrome, an extrapyramidal or movement disorder, a motor disorder, a hyperkinetic movement disorder, a psychotic disorder, catatonia, a mood disorder, a depressive disorder, an anxiety disorder, obsessive-compulsive disorder (OCD), an autism spectrum disorder, a prolactin-related disorder (e.g., hyperprolactinemia), a neurocognitive disorder, a trauma- or stressor-related disorder (e.g., PTSD); a disruptive, impulse-control, or conduct disorder, a sleep-wake disorder, a substance-related disorder, an addictive disorder, a behavioral disorder, hypofrontality, an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway, decreased activity in the striatum, cortical dysfunction, neurocognitive dysfunction and the cognitive deficits associated with schizophrenia; Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy and progressive supranuclear palsy, and Huntington's disease, including chorea associated with Huntington's disease.
201 . A method of ameliorating one or more symptoms of a neurological disorder, comprising administering to a subject in need thereof an effective amount of at least one compound of any one of claims 1-198 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 199 ; wherein the neurological disorder is selected from the group consisting of:
schizophrenia, cognitive impairment, a panic disorder, a phobic disorder, drug-induced psychotic disorder, delusional psychosis, neuroleptic-induced dyskinesia, Parkinson's disease, drug-induced Parkinson's syndrome, extrapyramidal syndrome, Alzheimer's Disease, Lewy Body Dementia, bipolar disorder, ADHD, Tourette's syndrome, an extrapyramidal or movement disorder, a motor disorder, a hyperkinetic movement disorder, a psychotic disorder, catatonia, a mood disorder, a depressive disorder, an anxiety disorder, obsessive-compulsive disorder (OCD), an autism spectrum disorder, a prolactin-related disorder (e.g., hyperprolactinemia), a neurocognitive disorder, a trauma- or stressor-related disorder (e.g., PTSD); a disruptive, impulse-control, or conduct disorder, a sleep-wake disorder, a substance-related disorder, an addictive disorder, a behavioral disorder, hypofrontality, an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway, decreased activity in the striatum, cortical dysfunction, neurocognitive dysfunction and the cognitive deficits associated with schizophrenia; Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy and progressive supranuclear palsy, and Huntington's disease, including chorea associated with Huntington's disease.
202 . Use of a least one compound of any one of claims 1-198 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical product of claim 199 for treating a neurological disorder, wherein the neurological disorder is selected from the group consisting of schizophrenia, cognitive impairment, a panic disorder, a phobic disorder, drug-induced psychotic disorder, delusional psychosis, neuroleptic-induced dyskinesia, Parkinson's disease, drug-induced Parkinson's syndrome, extrapyramidal syndrome, Alzheimer's Disease, Lewy Body Dementia, bipolar disorder, ADHD, Tourette's syndrome, an extrapyramidal or movement disorder, a motor disorder, a hyperkinetic movement disorder, a psychotic disorder, catatonia, a mood disorder, a depressive disorder, an anxiety disorder, obsessive-compulsive disorder (OCD), an autism spectrum disorder, a prolactin-related disorder (e.g., hyperprolactinemia), a neurocognitive disorder, a trauma- or stressor-related disorder (e.g., PTSD); a disruptive, impulse-control, or conduct disorder, a sleep-wake disorder, a substance-related disorder, an addictive disorder, a behavioral disorder, hypofrontality, an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway, decreased activity in the striatum, cortical dysfunction, neurocognitive dysfunction and the cognitive deficits associated with schizophrenia; Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy and progressive supranuclear palsy, and Huntington's disease, including chorea associated with Huntington's disease.
203 . Use of a least one compound of any one of claims 1-198 or a pharmaceutically acceptable salt thereof, or the pharmaceutical product of claim 199 in a method of ameliorating one or more symptoms of a neurological disorder, wherein the neurological disorder is selected from the group consisting of schizophrenia, cognitive impairment, a panic disorder, a phobic disorder, drug-induced psychotic disorder, delusional psychosis, neuroleptic-induced dyskinesia, Parkinson's disease, drug-induced Parkinson's syndrome, extrapyramidal syndrome, Alzheimer's Disease, Lewy Body Dementia, bipolar disorder, ADHD, Tourette's syndrome, an extrapyramidal or movement disorder, a motor disorder, a hyperkinetic movement disorder, a psychotic disorder, catatonia, a mood disorder, a depressive disorder, an anxiety disorder, obsessive-compulsive disorder (OCD), an autism spectrum disorder, a prolactin-related disorder (e.g., hyperprolactinemia), a neurocognitive disorder, a trauma- or stressor-related disorder (e.g., PTSD); a disruptive, impulse-control, or conduct disorder, a sleep-wake disorder, a substance-related disorder, an addictive disorder, a behavioral disorder, hypofrontality, an abnormality in the tuberoinfundibular, mesolimbic, mesocortical, or nigrostriatal pathway, decreased activity in the striatum, cortical dysfunction, neurocognitive dysfunction and the cognitive deficits associated with schizophrenia; Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy and progressive supranuclear palsy, and Huntington's disease, including chorea associated with Huntington's disease.